Australian biotechnology company Cartherics, which is developing immune cell therapies for cancer and other diseases, has been awarded a US$300,000 G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials. …
Cartherics secures G-Rex grant to support its ‘in house’ manufacturing program
December 18, 2024 Australian Biotech
Latest Video
New Stories
-
Specialised Therapeutics expands partnership with Incyte to include two additional therapies
June 13, 2025 - - Latest News -
New immunisation strategy highlights COVID impact, priority patients and new technologies
June 12, 2025 - - Latest News -
Medicines Australia establishes radiopharmaceuticals working group
June 12, 2025 - - Latest News -
MSD Australia and New Zealand certified a 'Great Place to Work'
June 12, 2025 - - Latest News -
Specialised Therapeutics expands partnership with Incyte to include two additional therapies
June 12, 2025 - - Latest News -
Novo Nordisk partners with Heart of Australia to expand clinical trial access
June 12, 2025 - - Latest News -
Mark Butler starts the process of NDIS pricing reform
June 11, 2025 - - Latest News